公开(公告)号：US20160031827A1

公开(公告)日：2016-02-04

申请号：US14784147

申请日：2014-05-30

Applicant: KOWA COMPANY, LTD.

Inventor： Koichi YAMAZAKI ,  Kennosuke MATSUDA ,  Taichi KUSAKABE ,  Tadaaki OHGIYA ,  Kimiyuki SHIBUYA

IPC: C07D239/47

CPC classification number: C07D239/47 ,  C07B2200/13

Abstract: It is an object of the present invention to provide a novel form of (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl}acetic acid, which is useful for preventing and/or treating diseases such as dyslipidemia.(S)-trans-{4-[({2-[({1-[3,5-bis(Trifluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl}acetic acid hydrochloride.

Abstract translation: 本发明的目的是提供（S） - 反 - {4 - [（{2 - [（{1- [3,5-双（三氟甲基）苯基]乙基} {5- [ 2-（甲基磺酰基）乙氧基]嘧啶-2-基}氨基）甲基] -4-（三氟甲基）苯基}（乙基）氨基）甲基]环己基}乙酸，其可用于预防和/或治疗诸如血脂异常 。 （S） - 反 - {4 - [（{2 - [（{1- [3,5-双（三氟甲基）苯基]乙基} {5- [2-（甲基磺酰基）乙氧基]嘧啶-2-基} ）甲基] -4-（三氟甲基）苯基}（乙基）氨基）甲基]环己基}乙酸盐酸盐。

公开(公告)号：US20150218151A1

公开(公告)日：2015-08-06

申请号：US14427865

申请日：2013-09-25

Applicant: KOWA COMPANY, LTD.

Inventor： Takahisa Ogamino ,  Shin Tanikawa ,  Yoshiharu Miyake ,  Shinsuke Itoh ,  Yoshikazu Sawada

IPC: C07D417/14 ,  C07D403/12 ,  C07D401/12 ,  C07D417/12

CPC classification number: C07D417/14 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/497 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: The present invention is to create a compound that selectively activates glucokinase in the liver, and in particular, to provide an agent for treating and preventing diabetes and impaired glucose tolerance, wherein the agent has a low hypoglycemia risk.A compound represented by the formula (1) as shown below, or a salt thereof, or a solvate of the compound or the salt:[wherein, in the following formula (1), ring A represents a thiazolyl group, a pyridyl group, a pyrazyl group, or a pyrazolyl group; L represents —(CO)—, —(CS)—, or —SO2—; and R1 represents a C1-6 alkyl group, a hydroxy C1-6 alkyl group, a C1-6 alkoxy group, an amino group, a C1-6 alkylamino group, a hydroxyamino group, an N—C1-6 alkylcarbamoyl group, or a group represented by the formula (2) as shown below, wherein R3 represents a C1-6 alkyl group; and R2 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, or a carboxyl group].

Abstract translation: 本发明是产生选择性地激活肝脏中的葡萄糖激酶的化合物，特别是提供治疗和预防糖尿病和葡萄糖耐量降低的药剂，其中该药物具有低的低血糖风险。 由下式（1）表示的化合物或其盐或化合物或其盐的溶剂化物：[其中，在下式（1）中，环A表示噻唑基，吡啶基， 吡唑基或吡唑基; L代表 - （CO） - ， - （CS） - 或-SO2-; 和R 1表示C 1-6烷基，羟基C 1-6烷基，C 1-6烷氧基，氨基，C 1-6烷基氨基，羟基氨基，N-C 1-6烷基氨基甲酰基或 由下式（2）表示的基团，其中R 3表示C 1-6烷基; R 2表示氢原子，卤素原子，C 1-6烷基，C 1-6烷氧基或羧基。

公开(公告)号：US20150196538A1

公开(公告)日：2015-07-16

申请号：US14429449

申请日：2013-09-27

Applicant: KOWA COMPANY, LTD.

Inventor： Toshiaki Takizawa ,  Yasunobu Yoshinaka

IPC: A61K31/423 ,  A61K31/397

CPC classification number: A61K31/423 ,  A61K31/397 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.

Abstract translation: 本发明涉及提供用于预防和/或治疗诸如动脉粥样硬化，高胆固醇血症，包括人在内的哺乳动物中的低HDL血液病的血脂异常状况的药物组合组合物和药物组合的问题。 一种用于预防和/或治疗血脂异常等的药物组合物，其包含（a）由通式（1）表示的化合物（式中各符号与说明书中所定义的相同）或其盐 或其溶剂合物和（b）胆固醇吸收抑制剂。

公开(公告)号：US20140378441A1

公开(公告)日：2014-12-25

申请号：US14481467

申请日：2014-09-09

Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION ,  KOWA COMPANY, LTD.

Inventor： Tatsuro Ishibashi ,  Shintaro Nakao ,  Ryoichi Arita ,  Ken Mizuno ,  Akifumi Tsuchiura

IPC: A61K31/551 ,  A61K9/00

CPC classification number: A61K31/551 ,  A61K9/0046 ,  A61K9/0048 ,  A61K31/496 ,  A61K47/10 ,  C07D401/12

Abstract: Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient.

Abstract translation: 本文公开了眼底疾病，特别是糖尿病性视网膜病变或年龄相关性黄斑变性的预防或治疗剂。 眼底疾病的预防或治疗剂包括：（S） - （ - ） - 1-（4-氟-5-异喹啉磺酰基）-2-甲基-1,4-高哌嗪，其盐或其溶剂合物， 作为活性成分。

公开(公告)号：US20020099074A1

公开(公告)日：2002-07-25

申请号：US10034669

申请日：2001-12-19

Applicant: Kowa Company, Ltd.,Japan

Inventor： Kimiyuki Shibuya ,  Katsumi Kawamine ,  Yukihiro Sato ,  Toshiyuki Edano ,  Mitsuteru Hirata ,  Chiyoka Ozaki

IPC: C07D513/02 ,  C07D471/02 ,  A61K031/4745 ,  A61K031/423 ,  A61K031/428 ,  A61K031/4184

CPC classification number: C07D263/58 ,  C07D233/84 ,  C07D235/28 ,  C07D263/60 ,  C07D277/74 ,  C07D413/04 ,  C07D413/12 ,  C07D471/04

Abstract: The invention relates to a novel anilide compound and a pharmaceutical composition comprising the same. The invention relates to a compound represented by the following general formula: 1 represents a divalent residue of benzene with a substituent(s), heterocycle-condensed benzene which may or may not have a substituent, pyridine which may or may not have a substituent, cyclohexane or naphthalene 2 Ar represents an aryl group which may or may not have a substituent, X represents nullNHnull, oxygen atom or sulfur atom; Y represents nullNR4null, oxygen atom, sulfur atom, sulfoxide or sulfone; Z represents single bond or nullNR5null; R4 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; R5 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; and n represents an integer of 0 to 15. The inventive compounds are useful in the form of pharmaceutical composition, specifically as acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitor.

Abstract translation: 本发明涉及一种新的酰苯胺化合物和包含其的药物组合物。 本发明涉及由以下通式表示的化合物：表示具有取代基的苯的二价残基，可以具有也可以不具有取代基的杂环稠合苯，可以具有也可以不具有取代基的吡啶，可以不具有取代基的吡啶，环己烷 或萘Ar表示可以具有或不具有取代基的芳基，X表示-NH-，氧原子或硫原子; Y代表-NR4-，氧原子，硫原子，亚砜或砜; Z表示单键或-NR5-; R4表示氢原子，低级烷基，芳基或可以具有取代基的甲硅烷基化低级烷基; R5表示氢原子，低级烷基，芳基或可具有取代基的甲硅烷基化低级烷基; 并且n表示0至15的整数。本发明化合物可以以药物组合物的形式使用，特别是作为酰基辅酶A胆固醇酰基转移酶（ACAT）抑制剂。

公开(公告)号：US20240369737A1

公开(公告)日：2024-11-07

申请号：US18650809

申请日：2024-04-30

Applicant: KOWA COMPANY, LTD.

Inventor： Kentaro IWAMI ,  Hideki INA ,  Jun MARUYAMA

IPC: G02B1/00 ,  G02B27/00

Abstract: An optical element and an optical design method to improve optical characteristics are provided. The optical element includes: a metalens having a finely shaped surface on which a fine pattern is formed based on a shape of a meta-atom and a bonded surface formed in a flat shape; and a bonding lens having a feature equivalent to an existing lens and bonded to the bonded surface. For example, the bonding lens includes at least: a first glass material bonded to the bonded surface; and a second glass material separated from the bonded surface and bonded to the first glass material. For example, the optical design method includes: a setting step of setting, based on optical design of a configuration including binary optics replacing a feature of the metalens, a first step pattern of the binary optics; a first calculation step; and a first identification step.

公开(公告)号：US20240306906A1

公开(公告)日：2024-09-19

申请号：US18280313

申请日：2022-03-10

Applicant: KOWA COMPANY, LTD.

Inventor： Takuya HARA

IPC: A61B3/00 ,  A61B3/12

CPC classification number: A61B3/0075 ,  A61B3/12

Abstract: An ophthalmic device (1) of the present invention has an optical head (2) including a light projection optical system (21) that projects light onto a subject eye (E), a light reception optical system (22) that receives light from the subject eye (E), and a fixation lamp (23) for guiding a line-of-sight direction of the subject eye (E), and a turning drive unit that turns the optical head (2) in a horizontal direction while maintaining positional relationships between the light projection optical system (21), the light reception optical system (22), and the fixation lamp (23). The turning drive unit is composed of a rotational drive unit (4) that rotates the optical head (2) in the horizontal direction and a horizontal drive unit (3) that moves the optical head (2) in the horizontal direction.

公开(公告)号：US12042483B2

公开(公告)日：2024-07-23

申请号：US17515945

申请日：2021-11-01

Applicant: Kowa Company, Ltd.

Inventor： Yusuke Sasaki ,  Masato Asahiyama ,  Toshiya Tanaka

IPC: A61K31/423 ,  A61P1/16 ,  A61K31/7034 ,  A61K31/7048

CPC classification number: A61K31/423 ,  A61P1/16 ,  A61K31/7034 ,  A61K31/7048

Abstract: The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) α agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

公开(公告)号：US12037708B2

公开(公告)日：2024-07-16

申请号：US17046467

申请日：2019-04-16

Applicant: NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION ,  KOWA COMPANY, LTD.

Inventor： Taiyo Yoshioka ,  Tsunenori Kameda ,  Akimune Asanuma ,  Keitaro Hattori ,  Norihiko Fukuoka

IPC: D01B7/00 ,  A01K67/04 ,  D01C3/02

CPC classification number: D01B7/00 ,  A01K67/04 ,  D01C3/02

Abstract: Provided is a method developed for producing a thread bundle with high efficiency in terms of spun thread collection and without causing mechanical damage to a foothold silk thread spun by a bagworm onto a base material. After a bagworm is placed along with a solvent-soluble base material and allowed to spin the foothold silk thread onto the surface of the base material, the base material is dissolved with a solvent to separate the foothold silk thread therefrom.

公开(公告)号：US20240216342A1

公开(公告)日：2024-07-04

申请号：US18556912

申请日：2022-04-27

Applicant: KOWA COMPANY, LTD.

Inventor： Ryohei TANIGAWA ,  Ayumi SAITO ,  Kaho IKEGAMI

IPC: A61K31/423 ,  A61K31/205 ,  A61P3/00

CPC classification number: A61K31/423 ,  A61K31/205 ,  A61P3/00

Abstract: Provided is a novel preventing and/or treating agent useful for prevention and/or treatment of carnitine deficiency, or a disease for which supplementation of carnitine may have a therapeutic effect. The present invention relates to a medicament for preventing and/or treating carnitine deficiency, or a disease for which supplementation of carnitine may have a therapeutic effect, the medicament comprising a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof.